MRCP PACES Renal Cases: Applying Guidelines With Confidence

Renal medicine is one of the highest-yield specialties in the MRCP PACES exam. Every diet lists at least one candidate who failed Station 2 or Station 5 because they could not anchor their findings to NICE and KDIGO guidance, or because their management plan drifted away from what the examiners were clearly steering them toward. The good news is that renal PACES scenarios are predictable, the guidelines are well defined, and a focused, guideline-aware approach will lift your score more than any amount of last-minute textbook reading.

This blog walks you through how to use renal guidelines confidently in the PACES consultation, how to integrate them into your physical examination, and how to avoid the silent failures that examiners flag every diet.

Why Renal Cases Appear So Often in PACES

Renal disease is common, multisystem, and lends itself to a Station 1 (physical signs), Station 2 (history), or Station 5 (consultation) format. Typical PACES renal cases include:

• Chronic kidney disease (CKD) from diabetic nephropathy, hypertensive nephrosclerosis, or autosomal dominant polycystic kidney disease (ADPKD)

• Renal transplantation follow-up

• Nephrotic syndrome in adults

• AV fistula in a haemodialysis patient

• Glomerulonephritis presenting with haematuria and proteinuria

• Renovascular disease in a young or older patient

• Diabetic kidney disease with overlapping cardiovascular findings

• Hereditary renal disease (ADPKD, Alport syndrome, Fabry disease)

In the new PACES23 format, these cases are often wrapped inside an integrated clinical assessment where you must combine examination findings with a patient-centred discussion of management. That is exactly where guidelines become your safety net.

The Core Guidelines You Must Know

You do not need to memorise every line of every guideline. You need to know the framework and the thresholds that drive decisions.

1. NICE Chronic Kidney Disease Guideline (NG203)

This is your anchor document for almost every CKD case.

• Diagnosis: eGFR < 60 mL/min/1.73 m² for more than 3 months, with or without markers of kidney damage.

• Staging: Use the G1–G5 categories (G1 ≥ 90, G2 60–89, G3a 45–59, G3b 30–44, G4 15–29, G5 < 15) combined with albuminuria categories A1, A2, A3.

• ACE inhibitors or ARBs first-line for proteinuric CKD (urine ACR ≥ 30 mg/mmol), titrated up if tolerated.

• SGLT2 inhibitors (dapagliflozin, empagliflozin) recommended for CKD with eGFR 20–45 mL/min/1.73 m² across diabetic and non-diabetic aetiology, per NICE and KDIGO 2022/2024 updates.

• Referral thresholds: eGFR < 30, ACR > 70, rapidly declining eGFR (> 5 mL/min/year), suspected renal artery stenosis, or complicated hypertension.

• BP target: ≤ 130/80 in CKD with albuminuria; ≤ 140/90 in CKD without albuminuria (per NICE NG203).

2. NICE Acute Kidney Injury Guideline (NG148)

PACES rarely gives you an acutely unwell patient, but the consultation may ask "what would you do if this patient's creatinine suddenly doubled?"

• Risk factors: dehydration, sepsis, nephrotoxins (NSAIDs, ACEi/ARBs, contrast), obstruction, hypovolaemia.

• Staging: based on creatinine rise and urine output (AKIN/KDIGO criteria).

• Management: treat the cause, stop nephrotoxins, restore perfusion, monitor fluid balance, investigate obstruction (post-renal AKI), refer to nephrology when indicated.

3. NICE Anaemia of Chronic Kidney Disease Guideline (NG203)

This is a frequent PACES trap because the patient often looks pale and you may see a fistula or transplant scar.

• Diagnostic workup: full blood count, ferritin, transferrin saturation, B12, folate, reticulocyte count, and rule out other causes before attributing to CKD.

• Iron: IV iron first-line for haemodialysis-dependent patients; consider IV or oral iron for non-dialysis patients with TSAT < 20% or ferritin < 100 µg/L.

• ESAs: start if Hb < 100 g/L after iron repletion, aiming for 100–120 g/L.

• Avoid transfusion unless symptomatic or Hb < 70 g/L, especially in transplant candidates.

4. NICE Renal Replacement Therapy and Conservative Management Guideline (NG107)

This is essential for Station 5 conversations about dialysis decisions.

• Prepare for RRT when eGFR < 20 with progressive decline, or 6–12 months before anticipated dialysis start.

• Discuss conservative management as an equal option alongside dialysis, especially in frail patients or those with high comorbidity burden.

• Modality choice: haemodialysis, peritoneal dialysis, transplantation, or conservative care.

5. UK Kidney Association and KDIGO Glomerulonephritis Guidelines

For nephrotic syndrome and GN cases:

• Minimal change disease: first-line high-dose corticosteroids; cyclophosphamide, ciclosporin, or rituximab for relapse or steroid resistance.

• Membranous nephropathy: KDIGO 2021 supports initial conservative management for low-risk patients, with immunosuppression (cyclophosphamide + steroids, or rituximab) for high-risk patients.

• IgA nephropathy: supportive care (BP control, SGLT2 inhibitors) first; targeted-release budesonide (Nefecon) per NICE TA948 for progressive disease; immunosuppression for high-risk disease.

• ANCA-associated vasculitis: rituximab or cyclophosphamide induction; rituximab maintenance.

6. NICE Hypertension Guideline (NG136) and Lipid Modification (NG238)

Most renal PACES patients are hypertensive and dyslipidaemic. You must integrate these into your plan.

• BP target: ≤ 130/80 in CKD with albuminuria.

• Statins: Atorvastatin 20 mg for primary prevention in CKD; 80 mg in established cardiovascular disease.

Linking Physical Signs to Guidelines in Station 1

Examiners in PACES are testing whether your findings connect to a coherent clinical reasoning chain. When you spot a renal sign, do not stop at the name. Use guidelines to demonstrate depth.

A good PACES candidate walks in, sees a renal transplant scar, and says: "This is a renal transplant patient. I will examine for signs of rejection, infection, and complications of immunosuppression, including skin malignancy. I will check the eGFR, tacrolimus or ciclosporin level, CMV status, and urine protein." That is the kind of structured, guideline-aware thinking examiners reward.

Station 2: History Taking in Renal Cases

Station 2 often frames a renal case as a vague symptom such as fatigue, oedema, or altered urine. Your guideline awareness should shape the questions you ask.

Suggested structured history framework

• Presenting complaint: open question, then specific probes (oedema onset, urine output, urine colour, froth, nocturia, fatigue, breathlessness).

• Risk factors: diabetes duration and control, hypertension, ischaemic heart disease, peripheral vascular disease, recurrent UTIs, stones, family history of renal disease.

• Drugs and nephrotoxins: NSAIDs, ACEi/ARB, diuretics, lithium, calcineurin inhibitors, bisphosphonates, proton pump inhibitors, herbal remedies, recent contrast exposure.

• Systemic features: rashes (lupus, vasculitis), joint pains (SLE, IgA), haemoptysis (vasculitis), sinusitis (GPA), hearing loss (Alport), red eyes (IgA).

• Social and functional impact: work, diet, fluid restriction adherence, family planning, travel for dialysis.

• Psychological impact: anxiety about dialysis, transplant waiting list, body image with fistula.

The guideline-aware question that impresses examiners

• "Given that you have CKD stage 4 with proteinuria, I would want to confirm that you are on the maximum tolerated dose of an ACE inhibitor or ARB, and that we have considered an SGLT2 inhibitor per NICE NG203."

• "If you developed sudden weight gain, breathlessness, and reduced urine output, that would raise concern for AKI, and we would review your medications and consider stopping the ACE inhibitor temporarily."

These phrases signal that you understand the threshold-driven logic of guidelines rather than reciting risk factors.

Station 5: Consultation Mastery With Renal Guidelines

Station 5 is where guidelines become a clinical lifeline. The scenario is typically a follow-up discussion after breaking bad news, or a decision conversation about dialysis, transplantation, or conservative management.

Common Station 5 scenarios

1. Newly diagnosed CKD stage 4 — explaining progression, monitoring, and preparation for renal replacement therapy.

2. CKD patient declining dialysis — exploring reasons, addressing misconceptions, and offering conservative management.

3. Transplant recipient with rising creatinine — discussing possible rejection, drug levels, and the need for biopsy.

4. ADPKD patient considering tolvaptan — discussing NICE TA358 eligibility, liver function monitoring, and contraception.

5. Recurrent renal stones — discussing metabolic workup, hydration, dietary modification, and when to refer for surgical intervention.

6. Nephrotic syndrome relapse — discussing steroid side effects, second-line agents, and vaccination status before rituximab.

7. Diabetic patient with declining eGFR — discussing renoprotective triple therapy (ACEi/ARB + SGLT2i + non-steroidal MRA if appropriate, or GLP-1 RA).

The 5-step PACES consultation structure for renal cases

1. Open and summarise — "I can see from your notes that your kidney function has been slowly declining over the last two years. How are you feeling about that?"

2. Explore ideas, concerns, and expectations — uncover fears about dialysis, transplant waiting times, impact on work, and family history of renal disease.

3. Provide information in chunks — explain the eGFR trend, the reason for referral, and what preparation involves.

4. Shared decision-making — use NICE NG107 to frame modality choice as an equal triad of haemodialysis, peritoneal dialysis, and transplantation, with conservative care as the fourth option.

5. Safety net and follow-up — agree on a clear plan, red-flag symptoms (breathlessness, oedema, reduced urine, fever on dialysis), and next review.

Phrases that show guideline awareness

• "The NICE guideline recommends that we start discussing renal replacement therapy when eGFR falls below 20, so we are not at that point yet, but it is a good time to start thinking about it."

• "Conservative management is a recognised, evidence-based option for patients who do not wish to have dialysis, and the renal team will support you either way."

• "We can offer you tolvaptan because you meet the criteria in NICE TA358, but we need to monitor your liver function monthly for the first 18 months."

High-Yield PACES Renal Vignettes to Practise

To train yourself to integrate guidelines under time pressure, rehearse these short scenarios with a study partner or AI patient:

1. 62-year-old man with type 2 diabetes, eGFR 38, ACR 35 — what is the next step in management? (Add SGLT2 inhibitor per NICE NG203; titrate ACEi; review BP and statin.)

2. 34-year-old woman with newly diagnosed nephrotic syndrome — what is the first-line treatment? (Prednisolone 1 mg/kg per KDIGO 2021, with proton pump inhibitor, bone protection, and vaccination review.)

3. 58-year-old man with ADPKD, eGFR 35, rapidly progressing — what is the additional option? (Tolvaptan per NICE TA358, with monthly LFTs and effective contraception.)

4. 48-year-old transplant recipient with creatinine rising from 110 to 165 µmol/L — what are the priorities? (Check tacrolimus level, CMV PCR, BK virus, donor-specific antibodies, arrange biopsy.)

5. 72-year-old woman with CKD stage 4 who refuses dialysis — what is your approach? (Discuss conservative management, symptom control, advance care planning, and reassure that the team will support her decision.)

6. 29-year-old man with IgA nephropathy, proteinuria 1.5 g/day, eGFR 50 — what is the next step? (Maximise supportive care, including ACEi and SGLT2i, and consider targeted-release budesonide per NICE TA948.)

Common Pitfalls in Renal PACES Cases

1. Naming the sign without the guideline. "He has a fistula" is observation. "He has a functioning AV fistula for haemodialysis, and we should review access flow and dialysis adequacy per UKKA standards" is clinical reasoning.

2. Forgetting renoprotection. Every CKD patient discussion should include ACEi/ARB, SGLT2 inhibitor, BP target, statin, and lifestyle advice.

3. Ignoring anaemia workup. Many candidates skip the NICE NG203 anaemia pathway and jump straight to blood transfusion.

4. Missing drug interactions. Lithium, NSAIDs, ACEi/ARBs in dehydration, and contrast are classic nephrotoxins that examiners love to test.

5. Overpromising on dialysis. Modalities have specific indications; home haemodialysis is not for everyone, and peritoneal dialysis has contraindications (previous abdominal surgery, severe obesity, inflammatory bowel disease).

6. Skipping the patient's voice. PACES is a consultation, not a viva. Always check understanding and invite questions.

7. Missing vaccination and travel advice. Renal patients need annual influenza, COVID-19, pneumococcal, and hepatitis B vaccines, and live vaccines are contraindicated on immunosuppression.

A Practical Study Plan for Renal in MRCP PACES

• Week 1: Read NICE NG203, NICE NG107, and NICE NG148 summaries. Build a one-page algorithm for CKD staging, anaemia, and AKI.

• Week 2: Practice Station 1 with renal signs (fistula, transplant scar, polycystic kidneys, Cushingoid, oedema). Time yourself to 6 minutes.

• Week 3: Rehearse Station 2 histories with a focus on nephrotic syndrome, recurrent stones, and deteriorating CKD.

• Week 4: Run Station 5 scenarios with AI patients, including dialysis decision-making and tolvaptan counselling.

• Ongoing: Keep a renal PACES card with three columns — sign, guideline, and what to say. Review it the night before the exam.

Final Thought

Renal PACES is not about remembering every line of NICE or KDIGO. It is about building a structured, guideline-aware consultation that shows the examiner you can translate evidence into a safe, patient-centred plan. When you walk in and frame the case through the lens of NG203, NG107, NG148, and KDIGO, you stop sounding like a textbook and start sounding like a registrar. That shift is what separates a pass from a fail.

Practise deliberately, anchor every finding to a guideline, and your renal PACES stations will become some of the most reliable marks on the day.